mirabegron联合索非那新与索非那新单药治疗女性膀胱过动症的疗效、安全性、症状、生活质量及治疗依从性的比较研究

IF 0.7 Q4 UROLOGY & NEPHROLOGY
Rathindra Nath Ray, Anshu Kumar, Ruchita Agarwal, G S Kamilya, Taquedis Noori, Monika Shah
{"title":"mirabegron联合索非那新与索非那新单药治疗女性膀胱过动症的疗效、安全性、症状、生活质量及治疗依从性的比较研究","authors":"Rathindra Nath Ray, Anshu Kumar, Ruchita Agarwal, G S Kamilya, Taquedis Noori, Monika Shah","doi":"10.1177/03915603251378596","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Compared to other overactive bladder (OAB) symptoms, incontinence has a more negative impact on quality of life and is frequently challenging to treat with antimuscarinic monotherapy. This study's goal was to compare the safety, tolerability, and effectiveness of a combination of solifenacin 5 mg and mirabegron 25 mg or 50 mg versus solifenacin 5 mg in patients with OAB.</p><p><strong>Material and methods: </strong>In a tertiary care hospital, 258 individuals with overactive bladders participated in a randomised controlled open-label research to examine the safety and efficacy of mirabegron as a supplement to solifenacin. Randomisation was used to assign patients to one of three groups: those receiving solifenacin (5 mg) with mirabegron (25 mg), solifenacin (5 mg) plus mirabegron (50 mg) or solifenacin (5 mg) monotherapy. OABSS was used to examine the patients. A change in the OABSS from baseline to end of treatment (EOT) was the main outcome measure. This research also examined the safety and tolerability of combination treatment in comparison to solifenacin monotherapy.</p><p><strong>Results: </strong>All combinations with solifenacin five substantially improved the OAB symptoms score as compared to solifenacin 5 mg monotherapy. When compared to solifenacin 5 mg, both combination groups significantly decreased the frequency of micturition. Although there were no dose-related differences between the combination and monotherapy groups in terms of TEAEs, blood pressure, pulse rate, PVR volume, or laboratory or ECG parameters, combination medication did result in a slightly higher frequency of constipation.</p><p><strong>Conclusions: </strong>When compared to solifenacin 5 mg monotherapy, combination therapy with solifenacin/mirabegron markedly improved OABSS, micturition frequency, and urgency. When compared to monotherapy, all combinations were well tolerated and showed no significant extra safety concerns.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251378596"},"PeriodicalIF":0.7000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder - A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence.\",\"authors\":\"Rathindra Nath Ray, Anshu Kumar, Ruchita Agarwal, G S Kamilya, Taquedis Noori, Monika Shah\",\"doi\":\"10.1177/03915603251378596\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Compared to other overactive bladder (OAB) symptoms, incontinence has a more negative impact on quality of life and is frequently challenging to treat with antimuscarinic monotherapy. This study's goal was to compare the safety, tolerability, and effectiveness of a combination of solifenacin 5 mg and mirabegron 25 mg or 50 mg versus solifenacin 5 mg in patients with OAB.</p><p><strong>Material and methods: </strong>In a tertiary care hospital, 258 individuals with overactive bladders participated in a randomised controlled open-label research to examine the safety and efficacy of mirabegron as a supplement to solifenacin. Randomisation was used to assign patients to one of three groups: those receiving solifenacin (5 mg) with mirabegron (25 mg), solifenacin (5 mg) plus mirabegron (50 mg) or solifenacin (5 mg) monotherapy. OABSS was used to examine the patients. A change in the OABSS from baseline to end of treatment (EOT) was the main outcome measure. This research also examined the safety and tolerability of combination treatment in comparison to solifenacin monotherapy.</p><p><strong>Results: </strong>All combinations with solifenacin five substantially improved the OAB symptoms score as compared to solifenacin 5 mg monotherapy. When compared to solifenacin 5 mg, both combination groups significantly decreased the frequency of micturition. Although there were no dose-related differences between the combination and monotherapy groups in terms of TEAEs, blood pressure, pulse rate, PVR volume, or laboratory or ECG parameters, combination medication did result in a slightly higher frequency of constipation.</p><p><strong>Conclusions: </strong>When compared to solifenacin 5 mg monotherapy, combination therapy with solifenacin/mirabegron markedly improved OABSS, micturition frequency, and urgency. When compared to monotherapy, all combinations were well tolerated and showed no significant extra safety concerns.</p>\",\"PeriodicalId\":23574,\"journal\":{\"name\":\"Urologia Journal\",\"volume\":\" \",\"pages\":\"3915603251378596\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologia Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/03915603251378596\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603251378596","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:与其他膀胱过动症(OAB)症状相比,尿失禁对生活质量有更大的负面影响,并且经常难以用抗毒蕈碱单药治疗。本研究的目的是比较索非那新5mg联合美拉比龙25mg或50mg与索非那新5mg在OAB患者中的安全性、耐受性和有效性。材料和方法:在一家三级保健医院,258名膀胱过度活跃的患者参加了一项随机对照开放标签研究,以检查mirabegron作为索非那新补充剂的安全性和有效性。随机化将患者分为三组:接受索利那新(5mg)联合美拉贝龙(25mg)、索利那新(5mg)加美拉贝龙(50mg)或索利那新(5mg)单药治疗的患者。采用OABSS对患者进行检查。OABSS从基线到治疗结束(EOT)的变化是主要的结果测量。该研究还检查了联合治疗与索利那新单药治疗的安全性和耐受性。结果:与索非那新5mg单药治疗相比,索非那新5的所有联合治疗均显著改善了OAB症状评分。与索利那新5mg组相比,两组的排尿频率均显著降低。尽管在teae、血压、脉搏率、PVR容积、实验室或ECG参数方面,联合用药组和单药组之间没有剂量相关的差异,但联合用药确实导致便秘的频率略高。结论:与索非那新5mg单药治疗相比,索非那新/米拉贝隆联合治疗可显著改善OABSS、排尿频率和尿急。与单药治疗相比,所有联合治疗耐受性良好,没有明显的额外安全问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder - A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence.

Purpose: Compared to other overactive bladder (OAB) symptoms, incontinence has a more negative impact on quality of life and is frequently challenging to treat with antimuscarinic monotherapy. This study's goal was to compare the safety, tolerability, and effectiveness of a combination of solifenacin 5 mg and mirabegron 25 mg or 50 mg versus solifenacin 5 mg in patients with OAB.

Material and methods: In a tertiary care hospital, 258 individuals with overactive bladders participated in a randomised controlled open-label research to examine the safety and efficacy of mirabegron as a supplement to solifenacin. Randomisation was used to assign patients to one of three groups: those receiving solifenacin (5 mg) with mirabegron (25 mg), solifenacin (5 mg) plus mirabegron (50 mg) or solifenacin (5 mg) monotherapy. OABSS was used to examine the patients. A change in the OABSS from baseline to end of treatment (EOT) was the main outcome measure. This research also examined the safety and tolerability of combination treatment in comparison to solifenacin monotherapy.

Results: All combinations with solifenacin five substantially improved the OAB symptoms score as compared to solifenacin 5 mg monotherapy. When compared to solifenacin 5 mg, both combination groups significantly decreased the frequency of micturition. Although there were no dose-related differences between the combination and monotherapy groups in terms of TEAEs, blood pressure, pulse rate, PVR volume, or laboratory or ECG parameters, combination medication did result in a slightly higher frequency of constipation.

Conclusions: When compared to solifenacin 5 mg monotherapy, combination therapy with solifenacin/mirabegron markedly improved OABSS, micturition frequency, and urgency. When compared to monotherapy, all combinations were well tolerated and showed no significant extra safety concerns.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Urologia Journal
Urologia Journal UROLOGY & NEPHROLOGY-
CiteScore
0.60
自引率
12.50%
发文量
66
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信